Kevin A Nguyen1, Jamil S Syed1, Carin R Espenschied2, Holly LaDuca2, Ansh M Bhagat1, Alfredo Suarez-Sarmiento1, Timothy K O'Rourke3, Karina L Brierley4, Erin W Hofstatter5, Brian Shuch1,6. 1. Department of Urology, Yale School of Medicine, New Haven, Connecticut. 2. Clinical Diagnostics, Ambry Genetics, Aliso Viejo, California. 3. Frank H. Netter MD School of Medicine at Quinnipiac University, North Haven, Connecticut. 4. Yale Cancer Genetics and Prevention Program, Smilow Cancer Hospital, New Haven, Connecticut. 5. Department of Medicine, Section of Medical Oncology, Yale School of Medicine, New Haven, Connecticut. 6. Department of Radiology, Yale School of Medicine, New Haven, Connecticut.
Abstract
BACKGROUND: Panel testing has been recently introduced to evaluate hereditary cancer; however, limited information is available regarding its use in kidney cancer. METHODS: The authors retrospectively reviewed test results and clinical data from patients who underwent targeted multigene panel testing of up to 19 genes associated with hereditary kidney cancer from 2013 to 2016. The frequency of positive (mutation/variant likely pathogenic), inconclusive (variant of unknown significance), and negative results was evaluated. A logistic regression analysis evaluated predictive factors for a positive test. RESULTS: Patients (n = 1235) had a median age at diagnosis of 46 years, which was significantly younger than the US population of individuals with kidney cancer (P < .0001). Overall, 6.1%, 75.5%, and 18.4% of individuals had positive, negative, and inconclusive results, respectively. The most commonly altered genes included folliculin (FLCN) and fumarate hydratase (FH), which were altered in 1.8% and 1.3% of patients, respectively. Tuberous Sclerosis Complex 2 (TSC2), mesenchymal epithelial transition factor proto-oncogene (MET), and PMS1 homolog 2 (PMS2) had the highest rates of variants of unknown significance, which were identified in 2.7%, 2.2%, and 1.7% of patients, respectively. Early age of onset was the only factor that was identified as predictive of a positive test on multivariate analysis (odds ratio, 0.975; P = .0052) and may be the only identifying characteristic of low-penetrant syndromes, such as those associated with MITF (melanogenesis-associated transcription factor) mutations, which do not have singular histology or a family history of kidney cancer. CONCLUSIONS: Panel tests may be particularly useful for patients who lack distinguishing clinical characteristics of known hereditary kidney cancer syndromes. The current results support the use of early age of onset for genetic counseling and/or testing. Cancer 2017;123:4363-71.
BACKGROUND: Panel testing has been recently introduced to evaluate hereditary cancer; however, limited information is available regarding its use in kidney cancer. METHODS: The authors retrospectively reviewed test results and clinical data from patients who underwent targeted multigene panel testing of up to 19 genes associated with hereditary kidney cancer from 2013 to 2016. The frequency of positive (mutation/variant likely pathogenic), inconclusive (variant of unknown significance), and negative results was evaluated. A logistic regression analysis evaluated predictive factors for a positive test. RESULTS:Patients (n = 1235) had a median age at diagnosis of 46 years, which was significantly younger than the US population of individuals with kidney cancer (P < .0001). Overall, 6.1%, 75.5%, and 18.4% of individuals had positive, negative, and inconclusive results, respectively. The most commonly altered genes included folliculin (FLCN) and fumarate hydratase (FH), which were altered in 1.8% and 1.3% of patients, respectively. Tuberous Sclerosis Complex 2 (TSC2), mesenchymal epithelial transition factor proto-oncogene (MET), and PMS1 homolog 2 (PMS2) had the highest rates of variants of unknown significance, which were identified in 2.7%, 2.2%, and 1.7% of patients, respectively. Early age of onset was the only factor that was identified as predictive of a positive test on multivariate analysis (odds ratio, 0.975; P = .0052) and may be the only identifying characteristic of low-penetrant syndromes, such as those associated with MITF (melanogenesis-associated transcription factor) mutations, which do not have singular histology or a family history of kidney cancer. CONCLUSIONS: Panel tests may be particularly useful for patients who lack distinguishing clinical characteristics of known hereditary kidney cancer syndromes. The current results support the use of early age of onset for genetic counseling and/or testing. Cancer 2017;123:4363-71.
Authors: Maria I Carlo; A Ari Hakimi; Grant D Stewart; Gennady Bratslavsky; James Brugarolas; Ying-Bei Chen; W Marston Linehan; Eamonn R Maher; Maria J Merino; Kenneth Offit; Victor E Reuter; Brian Shuch; Jonathan A Coleman Journal: Eur Urol Date: 2019-07-18 Impact factor: 20.096
Authors: Maria I Carlo; Semanti Mukherjee; Diana Mandelker; Joseph Vijai; Yelena Kemel; Liying Zhang; Andrea Knezevic; Sujata Patil; Ozge Ceyhan-Birsoy; Kuo-Cheng Huang; Almedina Redzematovic; Devyn T Coskey; Carolyn Stewart; Nisha Pradhan; Angela G Arnold; A Ari Hakimi; Ying-Bei Chen; Jonathan A Coleman; David M Hyman; Marc Ladanyi; Karen A Cadoo; Michael F Walsh; Zsofia K Stadler; Chung-Han Lee; Darren R Feldman; Martin H Voss; Mark Robson; Robert J Motzer; Kenneth Offit Journal: JAMA Oncol Date: 2018-09-01 Impact factor: 31.777
Authors: Hong Truong; Rania Sheikh; Ritesh Kotecha; Yelena Kemel; Peter A Reisz; Andrew T Lenis; Nikita N Mehta; Aliya Khurram; Vijai Joseph; Diana Mandelker; Alicia Latham; Ozge Ceyhan-Birsoy; Marc Ladanyi; Neil J Shah; Michael F Walsh; Martin H Voss; Chung-Han Lee; Paul Russo; Jonathan A Coleman; A Ari Hakimi; Darren R Feldman; Zsofia K Stadler; Mark E Robson; Robert J Motzer; Kenneth Offit; Sujata Patil; Maria I Carlo Journal: Eur Urol Oncol Date: 2021-10-12
Authors: Sounak Gupta; Lori A Erickson; Christine M Lohse; Wei Shen; Beth A Pitel; Shannon M Knight; Kevin C Halling; Loren Herrera-Hernandez; Stephen A Boorjian; R Houston Thompson; Bradley C Leibovich; Rafael E Jimenez; John C Cheville Journal: JAMA Netw Open Date: 2021-11-01
Authors: Gennady Bratslavsky; Neil Mendhiratta; Michael Daneshvar; James Brugarolas; Mark W Ball; Adam Metwalli; Katherine L Nathanson; Phillip M Pierorazio; Ronald S Boris; Eric A Singer; Maria I Carlo; Mary B Daly; Elizabeth P Henske; Colette Hyatt; Lindsay Middleton; Gloria Morris; Anhyo Jeong; Vivek Narayan; W Kimryn Rathmell; Ulka Vaishampayan; Bruce H Lee; Dena Battle; Michael J Hall; Khaled Hafez; Michael A S Jewett; Christina Karamboulas; Sumanta K Pal; A Ari Hakimi; Alexander Kutikov; Othon Iliopoulos; W Marston Linehan; Eric Jonasch; Ramaprasad Srinivasan; Brian Shuch Journal: Cancer Date: 2021-08-03 Impact factor: 6.860
Authors: Martin Lang; Cathy D Vocke; Christopher J Ricketts; Adam R Metwalli; Mark W Ball; Laura S Schmidt; William M Linehan Journal: Urology Date: 2020-11-24 Impact factor: 2.649
Authors: Emmanuelle Nicolas; Elena V Demidova; Waleed Iqbal; Ilya G Serebriiskii; Ramilia Vlasenkova; Pooja Ghatalia; Yan Zhou; Kim Rainey; Andrea F Forman; Roland L Dunbrack; Erica A Golemis; Michael J Hall; Mary B Daly; Sanjeevani Arora Journal: Mol Genet Genomic Med Date: 2019-01-24 Impact factor: 2.183
Authors: Tiffiney R Hartman; Elena V Demidova; Randy W Lesh; Lily Hoang; Marcy Richardson; Andrea Forman; Lisa Kessler; Virginia Speare; Erica A Golemis; Michael J Hall; Mary B Daly; Sanjeevani Arora Journal: Sci Rep Date: 2020-08-11 Impact factor: 4.379